These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31586229)

  • 1. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis.
    Haussmann J; Tamaskovics B; Bölke E; Djiepmo-Njanang FJ; Kammers K; Corradini S; Hautmann M; Ghadjar P; Maas K; Schuler PJ; Hoffmann TK; Lammering G; Budach W; Matuschek C
    Strahlenther Onkol; 2019 Dec; 195(12):1041-1049. PubMed ID: 31586229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial.
    Jeremic B; Shibamoto Y; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J; Vaskovic Z; Tadic L
    J Clin Oncol; 2000 Apr; 18(7):1458-64. PubMed ID: 10735893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.
    Jeremic B; Milicic B; Dagovic A; Vaskovic Z; Tadic L
    J Clin Oncol; 2004 Sep; 22(17):3540-8. PubMed ID: 15337803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
    Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
    Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
    Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C
    Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
    Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
    Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
    Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
    Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
    Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience.
    Lavertu P; Adelstein DJ; Saxton JP; Secic M; Eliachar I; Strome M; Larto MA; Wood BG
    Arch Otolaryngol Head Neck Surg; 1999 Feb; 125(2):142-8. PubMed ID: 10037279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
    Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
    Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
    Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
    Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
    Magrini SM; Buglione M; Corvò R; Pirtoli L; Paiar F; Ponticelli P; Petrucci A; Bacigalupo A; Crociani M; Lastrucci L; Vecchio S; Bonomo P; Pasinetti N; Triggiani L; Cavagnini R; Costa L; Tonoli S; Maddalo M; Grisanti S
    J Clin Oncol; 2016 Feb; 34(5):427-35. PubMed ID: 26644536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Clin Transl Oncol; 2012 Aug; 14(8):613-8. PubMed ID: 22855143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.